Pulmonary embolism and thrombocytopenia induced by befotertinib
10.3760/cma.j.cn114015-20240311-00148
- VernacularTitle:贝福替尼致肺栓塞和血小板减少
- Author:
Ziqiong LIAO
1
;
Shujie DONG
1
;
Rongsheng ZHAO
1
Author Information
1. 北京大学第三医院药学部，北京 100191
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Pulmonary embolism;
Thrombocytopenia;
Befortinib;
EGFRTKI
- From:
Adverse Drug Reactions Journal
2024;26(4):251-253
- CountryChina
- Language:Chinese
-
Abstract:
A 63-year-old female patient with multiple systemic metastases from lung adenocarcinoma was treated with befotertinib (75 mg orally once daily) and other symptomatic supportive treatments. Before treatments, her platelet count (PLT) was 177×10 9/L. After 35 days of medication, the patient had a transient loss of consciousness with chest tightness and shortness of breath. Computed tomography pulmonary angiography showed multiple embolism in bilateral pulmonary arteries. Laboratory tests showed that D-dimer was 35.16 g/L, and PLT was 34×10 9/L. The pulmonary embolism and throm-bocytopenia were considered to be caused possibly by befotertinib. Befotertinib was stopped, and enoxaparin sodium injection and rivaroxaban were given successively for anticoagulation. Thirteen days later, the chest tightness and shortness of breath were significantly improved, D-dimer was 0.57 g/L, and the PLT was 123×10 9/L.
